Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244662 | 0.76 | KDM4E (0.41) | ALDH1A1KDM4EMAPTHPGDGAA | |
| SCHEMBL11389060 | 0.76 | KDM4E (0.41) | ALDH1A1KDM4EMAPTHPGDNCF1 | |
| SCHEMBL41506 | 0.74 | LCK (0.50) | ALDH1A1KDM4EMAPTHPGDGAA | |
| SCHEMBL29509257 | 0.74 | LCK (0.50) | ALDH1A1KDM4EMAPTHPGDGAA | |
| SCHEMBL1651399 | 0.73 | PDE10A (0.44) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| Hydrochloric Acid SCHEMBL29486326 | 0.72 | LCK (0.49) | ALDH1A1KDM4EMAPTHPGDGAA | |
| Hydrochloric Acid SCHEMBL3468306 | 0.72 | LCK (0.49) | ALDH1A1KDM4EMAPTHPGDGAA | |
| Hydrochloric Acid SCHEMBL28230152 | 0.72 | LCK (0.49) | ALDH1A1KDM4EMAPTHPGDGAA | |
| SCHEMBL6615577 | 0.72 | KDM4E (0.46) | ALDH1A1KDM4EMAPTHPGDGAA | |
| SCHEMBL7469665 | 0.72 | KDM4E (0.44) | ALDH1A1KDM4EMAPTHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423033-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-09 | — | — | US | claimed |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-06-05 | — | — | US | claimed |
| WO-2015027137-A1 | IMPROVED SYNTHESIS OF CAPURAMYCIN AND ITS ANALOGUES | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2015-02-26 | — | — | WO | disclosed |
| EP-1641781-B1 | Benzodiazepine CGRP receptor antagonists | MERCK SHARP & DOHME (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-1856100-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-05-05 | — | — | EP | disclosed |
| US-20100069373-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-18 | — | — | US | disclosed |
| EP-1641423-B1 | BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20100056501-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-7655647-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1289966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6503902-B2 | Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-02 | — | — | US | disclosed |
| US-20020025955-A1 | Substituted lactams as inhibitors of A beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-28 | — | — | US | disclosed |
| WO-2001077086-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DUPONT PHARMACEUTICALS COMPANY (US) | 2001-10-18 | — | — | WO | disclosed |
| US-5798353-A | Polysubstituted 3-acylamino-5-phenyl-1,4-benzodiazepin-2-one derivatives, process for their preparation and the pharmaceutical compositions containing them | SANOFI (FR) | 1998-08-25 | — | — | US | disclosed |
| US-5719143-A | Polysubstituted 3-acylamino-5-phenyl-1, 4-benzodiazepin-2-one derivatives, process for their preparation and the pharmaceutical compositions containing them | SANOFI (FR) | 1998-02-17 | — | — | US | disclosed |
| EP-0667344-A1 | 3-acylamino-5-(polysubstituted phenyl)-1,4-benzodiazepin-2-ones useful as CCK-receptor agonists | SANOFI (FR) | 1995-08-16 | — | — | EP | disclosed |
| EP-0620221-A1 | 5-Acylamino-1,2,4-thiadiazoles as cholecystokinine antagonists or agonists | ELF SANOFI (FR) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025955-A1 | Substituted lactams as inhibitors of A beta protein production | BACE1, APP, APH1A | ALDH1A1 3160/4885KDM4E 4310/4885MAPT 30/4885 |
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | ALDH1A1 3896/4885KDM4E 4239/4885MAPT 20/4885 |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | ALDH1A1 3896/4885KDM4E 4239/4885MAPT 20/4885 |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | ALDH1A1 2275/4885KDM4E 3505/4885MAPT 19/4885 |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | APP, APH1A, BACE1 | ALDH1A1 2084/4885KDM4E 3672/4885MAPT 39/4885 |
| US-20100069373-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BACE1, APP, BACE2 | ALDH1A1 3509/4885KDM4E 4231/4885MAPT 14/4885 |
| US-20100056501-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | ALDH1A1 3896/4885KDM4E 4239/4885MAPT 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.